Warning:
Passengers must have:
- a COVID-19 vaccination certificate showing that they were fully vaccinated with AstraZeneca (Vaxzevria), Covaxin, Covishield, Janssen, Medigen (MVC-COV1901), Moderna (Spikevax), Nuvaxovid (Novavax), Pfizer-BioNTech (Comirnaty), Sinopharm, Sinovac, Sputnik V or Turkovac at least 14 days before departure; or
- a COVID-19 vaccination certificate showing that they received one dose of AstraZeneca (Vaxzevria), Covaxin, Covishield, Janssen, Medigen (MVC-COV1901), Moderna (Spikevax), Nuvaxovid (Novavax), Pfizer-BioNTech (Comirnaty), Sinopharm, Sinovac, Sputnik V or Turkovac, and a COVID-19 recovery certificate; or
- a negative COVID-19 antigen or RT-PCR test result issued at most 72 hours before departure.

Type: Ok
Visa

The following should be taken into account even if holding a Visa:

Visa exempt visitors older than 12 years must hold sufficient funds to cover their stay (at least THB 20,000.- per person or THB 40,000.- per family). Proof of funds includes Letters of Credit, vouchers, Miscellaneous Charges Orders (MCO) or well-known credit cards, which are honored in Thailand.

Extension of stay is possible for visa exempt passengers.

Warning:

Visa exempt nationals must have passports and passport replacing documents with at least half an unused visa page for entry/departure endorsements by the Thai Immigration Service.

Purchase Visa Online

Type: Ok
HealthThis information is for guide purposes only. Other health organisations may recommend alternative precautions.

Exempt from Yellow Fever vaccination:

Passengers transiting countries with risk of yellow fever transmission if not disembarking the plane during transit.

Recommended:

Recommendation

Malaria prophylaxis: malaria risk exists throughout the year in rural, especially forested and hilly areas of the country mainly towards the international borders, including the southernmost provinces. There is no risk in cities (e.g. Bangkok, Chiang Mai city, Pattaya), urban areas, Samui island and the main tourist resorts of Phuket island. However, there is a risk in some other areas and islands. P. falciparum resistant to mefloquine and to quinine reported from areas near the borders with Cambodia and Myanmar. Artemisinin resistance reported near the border with Myanmar. P. vivax resistance to chloroquine reported. Human P. knowlesi infection reported. Recommended prevention in risk areas: A; in areas near Cambodia and Myanmar borders: C.

The WHO recommended type of prevention is referred to as:
- Type A (very limited risk of malaria transmission) - Mosquito bite prevention only.
- Type B (risk of non-falciparum malaria) - Mosquito-bite prevention plus chloroquine or doxycycline or atovaquone-proguanil or mefloquine chemoprophylaxis.
- Type C (risk of P. falciparum malaria) - Mosquito-bite prevention plus atovaquone-proguanil or doxycycline or mefloquine chemoprophylaxis.
Chemoprophylaxis should be started preferably one week before departure and no later than the first day of exposure; it must be taken with unfailing regularity and continued for 4 weeks after the last exposure. No prophylactic regimen is 100% protective against infection, but even if it fails to prevent the disease it may, nevertheless, render the infection milder and less life threatening.